Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Paclitaxel in Elderly Women With Ovarian Cancer
NCT00322881Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2006
- Primary completion
- Apr 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Completion rate of six cycles of carboplatin/paclitaxel with no dose reductions at 4.5 months. Started Apr 2006; status: terminated.
02
Drugs
carboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00322881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322881.